Last updated: 2026-09-06 05:39:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Arcus Biosciences, Inc. (RCUS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $29.65, with a market capitalisation of $3.84B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.04 to $31.74. This page covers its latest market performance, valuation, price trends and company information.
$3.84B | |
$29.64 | |
$49.10 | |
$6.30 | |
$30.13 | |
563.62K | |
1.29M | |
-- | |
$31.74 | |
$11.04 | |
-- | |
-- |
Arcus Biosciences, Inc. (RCUS) last closed at $30.13 as of 2026-09-04 23:31:00, unchanged from the previous close of $30.13.
During the latest regular trading session, RCUS traded between $6.30 and $49.10, with a volume of 563.62K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Arcus Biosciences, Inc. (RCUS) moved from $30.59 to $29.65, representing a decline of 3.06% ($0.94).
The stock traded between $28.23 and $31.47 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.03 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89.9%
RCUS is currently trading at $29.65, placing it 89.9% of the way from its 52-week low of $11.04 to its 52-week high of $31.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 601 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Arcus Biosciences, Inc. (RCUS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.